Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Mingxi Lin
Observed names:
M Lin,
M.-H. Lin,
Miao-Wen Lin
Institutions:
Shanghai Medical College of Fudan University,
Fudan University,
Fudan University Shanghai Cancer Center
Observed institutions:
Shanghai University,
Fujian Medical University,
Shanghai Medical College of Fudan University,
Fudan University,
Wenzhou Medical University,
Fudan University Shanghai Cancer Center,
Institute of Physics, Academia Sinica,
University of Chinese Academy of Sciences
show all 8
ORCID:
0000-0002-7435-4544
Observed ORCIDs:
0000-0002-7435-4544,
0000-0002-9745-9488
OpenAlex ID:
A5070128323
NF-κB in biology and targeted therapy: new insights and translational implications
2024
·
Qing Guo
, Yizi Jin
, et al.
·
Signal Transduction and Targeted Therapy
·
2,612
PDF
NF-κB signaling in therapy resistance of breast cancer: Mechanisms, approaches, and challenges
2024
·
Qing Guo
, Yizi Jin
, et al.
·
Life Sciences
·
57
Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis
2020
·
Ying Lin
, Mingxi Lin
, et al.
·
Cancer Research and Treatment
·
49
PDF
HER2‐low heterogeneity between primary and paired recurrent/metastatic breast cancer: Implications in treatment and prognosis
2023
·
Mingxi Lin
, Ting Luo
, et al.
·
Cancer
·
36
PDF
Astrocyte involvement in brain metastasis: from biological mechanisms to therapeutic strategies
2025
·
Teng Zhou
, Yuxin Yan
, et al.
·
Cancer and Metastasis Reviews
·
28
PDF
Comparative Overall Survival of CDK4/6 Inhibitors Plus Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive, HER2-negative metastatic breast cancer
2020
·
Mingxi Lin
, Yang Chen
, et al.
·
Journal of Cancer
·
25
PDF
Mutation analysis of 19 autosomal short tandem repeats in Chinese Han population from Shanghai
2016
·
Chengchen Shao
, Mingxi Lin
, et al.
·
International Journal of Legal Medicine
·
18
Overcoming matrix barriers for enhanced immune infiltration using siRNA-coated metal-organic frameworks
2025
·
Cheng Zeng
, Xiaojing Chen
, et al.
·
Acta Biomaterialia
·
16
A risk stratification model for predicting brain metastasis and brain screening benefit in patients with metastatic triple‐negative breast cancer
2020
·
Mingxi Lin
, Yizi Jin
, et al.
·
Cancer Medicine
·
14
PDF
Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases
2022
·
Mingxi Lin
, Yizi Jin
, et al.
·
International Journal of Cancer
·
11
PDF
Determination and clinical significance of bone pseudoprogression in hormone receptor-positive metastatic breast cancer
2021
·
Mingxi Lin
, Yizi Jin
, et al.
·
Therapeutic Advances in Medical Oncology
·
11
Cisplatin given at three divided doses for three consecutive days in metastatic breast cancer: an alternative schedule for one full dose with comparable efficacy but less CINV and hypomagnesaemia
2020
·
Jinfeng Zhang
, Mingxi Lin
, et al.
·
Breast Cancer Research and Treatment
·
10
COVID-ONE-hi: The One-Stop Database for COVID-19-Specific Humoral Immunity and Clinical Parameters
2021
·
Zhaowei Xu
, Yang Li
, et al.
·
Genomics Proteomics & Bioinformatics
·
9
PDF
Folate metabolism-associated CYP26A1 is a clinico-immune target in colorectal cancer
2025
·
Yifei Zhu
, Teng Zhou
, et al.
·
Genes and Immunity
·
8
PDF
Treatment patterns and clinical outcomes of chidamide combined with endocrine therapy in hormone receptor‐positive, HER2 ‐negative metastatic breast cancer: A real‐world multicenter study
2024
·
Doudou Li
, Yizi Jin
, et al.
·
Cancer Medicine
·
5
[Mechanisms mediating the inhibitory effects of quercetin against phthalates-induced testicular oxidative damage in rats].
2023
·
L Liu
, R Deng
, et al.
·
PubMed Central
·
5
PDF
Development and validation of a nomogram for predicting overall survival of patients with cancer of unknown primary: a real-world data analysis
2021
·
Yizi Jin
, Mingxi Lin
, et al.
·
Annals of Translational Medicine
·
5
PDF
Efficacy and safety of ARX788 for individuals with HER2-positive breast cancer and brain metastases (ACE-Breast-06): a single-arm, phase 2 trial in China
2025
·
Ting Li
, Mingxi Lin
, et al.
·
EClinicalMedicine
·
4
Efficacy of Trastuzumab Deruxtecan in HER2-Positive and HER2-Low Metastatic Breast Cancer: A Real-World Retrospective Cohort Study in China
2025
·
Yuxin Yan
, Yizi Jin
, et al.
·
Breast Cancer Targets and Therapy
·
4
PDF
c-di-GMP inhibits rRNA methylation and impairs ribosome assembly in the presence of kanamycin
2025
·
Siqi Yu
, Zheyao Hu
, et al.
·
EMBO Reports
·
4
PDF
Age- and Severity-Associated Humoral Immunity Response in COVID-19 Patients: A Cohort Study from Wuhan, China
2022
·
An Zhu
, Min Liu
, et al.
·
Journal of Clinical Medicine
·
3
PDF
SARS-CoV-2-specific antibody response characteristics in COVID-19 patients of different ages
2022
·
Linfang Lu
, Siqi Yu
, et al.
·
Acta Biochimica et Biophysica Sinica
·
3
PDF
Expert review on systemic treatment in the St. Gallen International Breast Cancer Conference 2021
2021
·
Mingxi Lin
, Yizi Jin
, et al.
·
Translational Breast Cancer Research
·
3
PDF
Complex I protein NDUFB9 is a metabolic vulnerability in triple negative breast cancer brain metastases
2026
·
Mingxi Lin
, Zhexu Wen
, et al.
·
Nature Communications
·
2
PDF
Results and Exploratory Biomarker Analyses of a Phase II Study CHANGEABLE: Combination of PD‐1 Inhibitor and Niraparib in GErm‐Line‐mutAted Metastatic Breast Cancer
2026
·
Jian Zhang
, Yiqun Du
, et al.
·
MedComm
·
2
Show more works
View as search
Works count:
42
Citation count:
2,948
H-index:
11
I10-index:
12
Year
Topic
Type